Progenics Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Progenics Pharmaceuticals's estimated annual revenue is currently $5.3M per year.
- Progenics Pharmaceuticals received $35.0M in venture funding in February 2014.
- Progenics Pharmaceuticals's estimated revenue per employee is $77,500
Employee Data
- Progenics Pharmaceuticals has 68 Employees.
- Progenics Pharmaceuticals grew their employee count by -14% last year.
Progenics Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate VP and Head Sales, PyL | Reveal Email/Phone |
2 | SVP Commercial | Reveal Email/Phone |
3 | vp Digital Technology | Reveal Email/Phone |
4 | SVP Quality | Reveal Email/Phone |
5 | Executive Director, Quality Assurance | Reveal Email/Phone |
6 | Senior Director, Medical Information, Drug Safety and Pharmacovigilance Operations | Reveal Email/Phone |
7 | Distinguished Director Intellectual Property | Reveal Email/Phone |
8 | Senior Director Clinical Research | Reveal Email/Phone |
9 | Director, Clinical Operations | Reveal Email/Phone |
10 | Regional Business Director | Reveal Email/Phone |
Progenics Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Progenics Pharmaceuticals?
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc. company. For additional information, please visit www.progenics.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
N/A
Total Funding
68
Number of Employees
$5.3M
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Progenics Pharmaceuticals News
Progenics Pharmaceuticals, Inc, AstraZeneca, Advanced Accelerator Applications, Jubilant Life Sciences Ltd, Pfizer Inc, Teva Pharmaceutical...
Salix, which specializes in gastrointestinal treatments, could pay Progenics another $90 million if the company reaches certain regulatory milestones in the United States. Salix will fund development, registration and commercialization costs for Relistor in all markets except for Japan, where On ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.3M | 68 | -32% | $33.1M |
#2 | $13.5M | 68 | -28% | N/A |
#3 | $9.2M | 68 | 6% | N/A |
#4 | $7.3M | 68 | 28% | N/A |
#5 | $8.9M | 68 | 3% | N/A |
Progenics Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-09-30 | $28.6M | NIH Grant | Article | |
| 2013-06-21 | $37.4M | Undisclosed | Jefferies LLC | Article |
| 2014-02-24 | $35.0M | Undisclosed | Jefferies LLC | Article |